WO2023089503 - INTER-ALPHA INHIBITOR PROTEIN FORMULATIONS
National phase entry is expected:
Publication Number
WO/2023/089503
Publication Date
25.05.2023
International Application No.
PCT/IB2022/061044
International Filing Date
16.11.2022
Title **
[English]
INTER-ALPHA INHIBITOR PROTEIN FORMULATIONS
[French]
FORMULATIONS DE PROTÉINE INHIBITRICE INTER-ALPHA
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
HÖFINGHOFF, Joris
DE ALMEIDA RIBEIRO JR., Euripedes
PICHLER, Sandra
Inventors
HÖFINGHOFF, Joris
DE ALMEIDA RIBEIRO JR., Euripedes
PICHLER, Sandra
Priority Data
63/280,057
16.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2864 | |
| EPO | Filing, Examination, Granting | 21740 | |
| Japan | Filing, Examination, Granting | 2993 | |
| South Korea | Filing, Examination, Granting | 3579 | |
| USA | Filing, Examination, Granting | 11340 |
Total:
42,516
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Liquid IαI and PαI formulations are described.[French]
L'invention concerne des formulations liquides d'IαI et de PαI.